[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100478274":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":25,"locations":25,"responsibleParty":26,"collaborators":25,"id":30,"slug":31,"hasResults":32,"nctId":33,"briefTitle":34,"officialTitle":34,"acronym":25,"eligibilityCriteria":35,"healthyVolunteers":32,"sex":36,"minAge":37,"maxAge":25,"enrollmentInfo":38,"targetDuration":25,"studyType":41,"phases":42,"briefSummary":44,"conditions":45,"keywords":48,"overallStatus":50,"whyStopped":25,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":25},{"fullName":5,"class":6},"Oslo University Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention","EXPERIMENTAL","Near or infra red light provided by the Valeda machine will be applied in the intervention eye",[13],"Device: Valeda machine",{"label":15,"type":16,"description":17,"interventionNames":18},"Control","SHAM_COMPARATOR","Light with very low intensity provided by the same Valeda machine will be applied in the control eye",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DEVICE","Valeda machine","Photobiomodulation treatment with Valeda machine will be applied every six months for 2 years in patients with dry age related macula degeneration.",[15,9],null,{"type":27,"investigatorFullName":28,"investigatorTitle":29,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","ANCA ROALD","Principal Investigator, MD dr. med.","100478274","photobiomodulation-for-dry-age-related-macula-degeneration-100478274",false,"NCT05507840","Photobiomodulation for Dry Age Related Macula Degeneration","Inclusion Criteria:\n\n* patients with dry AMD in the study eye and wet AMD in the control eye\n\nExclusion Criteria:\n\n* Geographic atrophy of the central macular region at enrolment\n* Previous\u002F active wet AMD in the study eye\n* A history of epilepsy\n* Retinal diseases apart from AMD\n* Significant media opacities\n* Cataracts worse than grade 2 (LOCS III classification)\n* Change in AREDS 2 supplements (vitamins) 1 month before the study and during the study trial was allowed.\n* Ongoing systemic medications that are photosensitizing (e.g. tetracyclins)\n* Systemic medications during the last 6 months that can cause deposits in the macular region (hydroxychloroquine, amiodarone)\n* Unable to give informed consent\n* Unable to cooperate with the treatment and follow-up","ALL","50 Years",{"count":39,"type":40},121,"ESTIMATED","INTERVENTIONAL",[43],"NA","The study will investigate the effect of photobiomodulation treatment on the risk of developing late age related macula degeneration (AMD) in the study eye in patients with wet AMD in the fellow eye.",[46,47],"Photobiomodulation","Age-Related Macular Degeneration",[49],"choroidal neovascular membrane","NOT_YET_RECRUITING","2022-10-11",{"date":53,"type":54},"2022-10-12","ACTUAL",{"date":56,"type":40},"2022-12-01",{"date":58,"type":40},"2027-12-01",{"name":5,"class":6}]